NCT03426254View on ClinicalTrials.gov

Comparison of Safety and Clinical Benefit of Injections Subcutaneously Talazoparib Versus Oral Talazoparib in Patients With Solid Tumors

PHASE1WithdrawnINTERVENTIONAL
0
Timeline

Start Date

November 10, 2022

Primary Completion Date

December 10, 2023

Study Completion Date

January 10, 2024

Conditions
Advanced or Recurrent Solid TumorsBreast Neoplasm
Interventions
BIOLOGICAL

Injections Subcutaneously Talazoparib

Patients receive per day single dose of subcutaneous Injection contains 1 mg Talazoparib on days 1-28

DRUG

Oral capsules Talazoparib

Patients receive 1 mg of Talazoparib PO QD on days 1-28.

Trial Locations (1)

1

University -Mother Theresa- Hospital, Oncology Dep., Tirana

Sponsors

Collaborators (1)

BioGene Pharmaceutical
All Listed Sponsors
collaborator

BioGene Pharmaceutical

UNKNOWN

lead

Center Trials & Treatment

OTHER

NCT03426254 - Comparison of Safety and Clinical Benefit of Injections Subcutaneously Talazoparib Versus Oral Talazoparib in Patients With Solid Tumors | Biotech Hunter | Biotech Hunter